Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies

Imagem de Miniatura
Arquivos
art_BELLESSO_Outpatient_treatment_with_intravenous_antimicrobial_therapy_and_oral_2011.PDF (294.8 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
PRACCHIA, Luis Fernando
Citação
ANNALS OF HEMATOLOGY, v.90, n.4, p.455-462, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The purpose of this study was to evaluate outcomes such as success of the initial therapy, failure of outpatient treatment, and death in outpatient treatment during intravenous antimicrobial therapy in patients with febrile neutropenia (FN) and hematological malignancies. In addition, clinical and laboratory data and the Multinational Association for Supportive Care of Cancer index (MASCC) were compared with failure of outpatient treatment and death. In a retrospective study, we evaluated FN following chemotherapy events that were treated initially with cefepime, with or without teicoplanin and replaced by levofloxacin after 48 h of defervescence in patients with good general conditions and ANC > 500/mm(3). Of the 178 FN episodes occurred in 126 patients, we observed success of the initial therapy in 63.5% of the events, failure of outpatient treatment in 20.8%, and death in 6.2%. The success rate of oral levofloxacin after defervescence was 99% (95 out of 96). Using multivariate analysis, significant risks of failure of outpatient treatment were found to be smoking (odds ratio (OR) 3.14, confidence interval (CI) 1.14-8.66; p = 0.027) and serum creatinine levels > 1.2 mg/dL (OR 7.97, CI 2.19-28.95; p = 0.002). With regard to death, the risk found was oxygen saturation by pulse oximetry < 95% (OR 5.8, IC 1.50-22.56; p = 0.011). Using the MASCC index, 165 events were classified as low risk and 13 as high risk. Failure of outpatient treatment was reported in seven (53.8%) high-risk and 30 (18.2%) low-risk episodes (p = 0.006). In addition, death occurred in seven (4.2%) low-risk and four (30.8%) high-risk events (p = 0.004). Ours results show that MASCC index was able to identify patients with high risk. In addition, non-smoking, serum creatinine levels a parts per thousand currency sign1.2 mg/dL, and oxygen saturation by pulse oximetry a parts per thousand yen95% were protection factors.
Palavras-chave
Febrile neutropenia, MASCC, Outpatient treatment
URI
https://observatorio.fm.usp.br/handle/OPI/23066
Referências
  1. TALCOTT JA, 1992, J CLIN ONCOL, V10, P316
  2. BODEY GP, 1966, ANN INTERN MED, V64, P328
  3. Minotti V, 1999, SUPPORT CARE CANCER, V7, P134, DOI 10.1007/s005200050243
  4. Klastersky J, 2000, J CLIN ONCOL, V18, P3038
  5. MOWER WR, 1995, CHEST, V108, P1297, DOI 10.1378/chest.108.5.1297
  6. Petrilli AS, 2000, MED PEDIATR ONCOL, V34, P87, DOI 10.1002/(SICI)1096-911X(200002)34:2<87::AID-MPO2>3.0.CO;2-F
  7. SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904
  8. Bennett CL, 2007, ONCOLOGIST, V12, P478, DOI 10.1634/theoncologist.12-4-478
  9. Freifeld A, 1999, NEW ENGL J MED, V341, P305, DOI 10.1056/NEJM199907293410501
  10. Viana LD, 2008, SUPPORT CARE CANCER, V16, P841, DOI 10.1007/s00520-007-0347-3
  11. Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215
  12. Klastersky J, 2006, J CLIN ONCOL, V24, P4129, DOI 10.1200/JCO.2005.03.9909
  13. Chamilos G, 2005, CANCER, V103, P2629, DOI 10.1002/cncr.21089
  14. Cherif H, 2006, HAEMATOL-HEMATOL J, V91, P215
  15. de Lalla F, 2003, PHARMACOECONOMICS, V21, P397, DOI 10.2165/00019053-200321060-00004
  16. Girmenia C, 1999, LEUKEMIA, V13, P514, DOI 10.1038/sj.leu.2401375
  17. Girmenia C, 1999, HAEMATOLOGICA, V84, P814
  18. Girmenia C, 2007, ANN HEMATOL, V86, P263, DOI 10.1007/s00277-006-0248-4
  19. Girmenia C, 1997, LEUKEMIA, V11, P1807, DOI 10.1038/sj.leu.2400851
  20. Kern WV, 1999, NEW ENGL J MED, V341, P312, DOI 10.1056/NEJM199907293410502
  21. LINDBERG LG, 1995, ACTA ANAESTH SCAND, V39, P279
  22. MALIK IA, 1995, AM J MED, V98, P224, DOI 10.1016/S0002-9343(99)80367-2
  23. MARTINO P, 1992, ONCOLOGY, V4, P49
  24. Schimpff S C, 1978, J Infect Dis, V137, P14
  25. SICKLES EA, 1975, ARCH INTERN MED, V135, P715, DOI 10.1001/archinte.135.5.715
  26. TALCOTT JA, 1988, ARCH INTERN MED, V148, P2561, DOI 10.1001/archinte.148.12.2561
  27. Talke Pekka, 2006, J Clin Monit Comput, V20, P305, DOI 10.1007/s10877-006-9022-3
  28. Uys A, 2004, SUPPORT CARE CANCER, V12, P555, DOI 10.1007/s00520-004-0614-5

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/54